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Musculoskeletal disorders (MSDs) comprise a 
wide range of conditions, associated with an enormous 
pain and impaired mobility, and are affecting people's 
lives and work. It is reported that 70%–84% of adults 
in the UK experience nonspecific low back pain(1) 
and 70% experience neck pain(2) during their lifetime. 
The incidence of MSDs appears to be increasing, 
with a corresponding impact on primary health care 
provision.(3) MSDs treatments cost $389 million to the 
retail industry in the US in 2007.(4) Annually in the UK 
they cost approximately ￡7.4 billion and cause ￡9.5 
million lost working days.(5) 
Management of MSDs typically involves a 
multidisciplinary team approach, including reduction 
in workload, increased rest, stress management, 
behavioural intervention and physiotherapy. Drug 
therapies include simple analgseics such as 
paracetamol, non-steroidal anti-inflammatory drugs 
(NSAIDs) such as ibuprofen, topically or systemically, 
opioids and tricyclic antidepressants; as well as 
surgery. Complementary and alternative medicine 
(CAM) is commonly used to treat musculoskeletal 
conditions, especially pain such as back pain, neck 
pain and shoulder pain.(6-8) The National Institute for 
Health and Clinical Excellences's (NICE) guideline on 
low back pain recommends consideration of manual 
therapy and acupuncture, traditionally considered 
CAM therapies.(9) 
A recent systematic review reported the 12-month 
prevalence of any use and visits to CAM practitioners in 
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15 countries, with prevalence ranging from 9.8%–76.0% 
for the use of any CAM and 1.8%–48.7% for visits 
to CAM practitioners, respectively.(10) An increasing 
number of English primary care practitioners offer CAM 
to their patients rising from 39% in 1995 to 50% in 
2001.(6) 
The Royal London Hospital for Integrated 
Medicine (RLHIM) is the largest public sector provider 
of integrated medicine in Europe and is part of 
University College London Hospitals (UCLH) National 
Health Service (NHS) Foundation Trust. MSDs are the 
most frequent reason for referral. In 2010, the hospital 
received over 15,000 patient referrals, of which 3,633 
cases (24.2%) were MSDs referrals.
The effectiveness of many complementary 
therapies for MSDs has been explored in previous 
studies, with some positive fi ndings.(11-14) However, little 
attention has been paid to evaluating of the effectiveness 
of integrated packages of care combining conventional 
and complementary approaches for MSDs in an NHS 
setting. Therefore, a feasibility study is required to pilot 
the study design in order to inform a future defi nitive trial. 
This study aims to determine the feasibility 
of all aspects of a pragmatic observational study 
designed: (1) to evaluate the effectiveness and cost 
effectiveness of integrated treatments for MSDs in an 
integrated NHS hospital in the UK; (2) to determine 
the acceptability of the study design and research 
process to patients; (3) to explore patients' expectation 
and experience of receiving integrated treatments.
METHODS
Setting and Design
This study will be conducted in the outpatient 
department at the RLHIM. It will use a pragmatic 
observational, mixed methods approach (quantitative 
and qualitative methods), with 1-year follow-up. 
Ethical Approval
Ethical approval for the study was obtained from 
City and East London Research Ethics Committee 
(REC reference number: 12/LO/1341). Anonymous 
data will be held securely and transferred only 
between the research team members.
Inclusion and Exclusion Criteria
This study will include all eligible patients with 
MSDs attending RLHIM in a 12-month period from 
January 2013 to January 2014. Table 1 shows the 
inclusion/exclusion criteria for the study. All eligible 
patients who give informed consent and indicate 
they are willing to participate in the study over the 
12-month period will be recruited.
Table 1. Study Eligibility Criteria
Inclusion criteria Exclusion criteria
1.  New referrals to RLHIM 
for MSDs; 
2.  Patients who are at least 16 
years old of both gender;
3.  Patients who have a primary 
diagnosis of ICD-10 codes-
musculoskeletal system and 
connective tissue;
4.  Patients who are able to 
take part in the study for 1 
year.
1.  Patients who are unwilling 
to take part in the study;
2.  Patients who are unable to 
speak English and therefore 
unable to understand the 
patient consent form or 
patient information form;
3.  Patients who have severe 
progressive disorders with 
life threatening condition or 
poor prognosis;
4.  Patients who have 
cognitive impairment 
such as dementia or 
psychological disorders.
Notes: Including all MSDs patients who have had 
treatment for MSDs previously but are now presenting for a 
new episode of care. Either a single MSDs diagnosis or with a 
combination MSDs diagnoses will be included; ICD, international 
classifi cation of diseases
Qualitative data will be collected both before and 
after treatment in a manner which will ensure that the 
views of a range of participants are reﬂ ected. Patients 
will be purposively selected on the basis of their 
expectations of benefit from the treatment, age and 
gender (at 1st interview, before treatment). A second 
sample of participants will be purposively selected 
following treatment based on the results of their 
SF-36™ Health Survey (SF-36), short form Brief Pain 
Inventory (BPI-sf), Patient Expectation Questionnaire 
(PEQ) scores, medical condition, age and gender. 
This data will be collected at the 2nd interview or 
focus group at 1 year starting treatment. 
Routine Practice for MSDs at RLHIM
Patients who present with MSDs typically 
receive integrated packages of care from RLHIM. The 
integrated packages of care combine conventional 
and complementary approaches, including dry 
needling and acupuncture, trigger point therapy, 
prolotherapy (injections to ligaments), homeopathy, 
phytothera, electrotherapies; medical manipulation, 
orthotics, cognitive behavioural therapy, occupational 
therapy, musculoskeletal physiotherapy, nutritional 
and dietary assessment and advice. 
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Figure 1. Musculoskeletal Care Pathway at RLHIM for Integrated Medicine 
Notes: CM: Chinese medicine; CBT: cognitive behaviour therapy
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Paper triage
A s  p e r  r o u t i n e  s t a n d a r d  p r a c t i c e ,  a l l 
musculoskeletal referrals to the RLHIM will be triaged 
by a specialist clinician and referred to various 
departments (Figure 1). All patients will be reassessed 
by a specialist clinician before being discharge. 
Participant Recruitment and Flow
Figure 2 details the process of recruitment 
and data collection procedures for the feasibility 
study. Patients will be screened using the inclusion/ 
exclusion criteria. Eligible patients will receive a 
Patient Information Sheet (PIS) and invitation letter, 
and a reminder about the study from the patient 
services department when arranging their hospital 
appointment. Patients will be further screened on 
the phone by the chief investigator (CI). Those 
providing verbal consent will be sent a questionnaire 
package including consent form, sociodemographic 
questionnaire, PEQ with a reply paid envelope to 
patients who are happy to be contacted. Those 
patients who provide written consent and return the 
questionnaires will be contacted by the CI to arrange 
a face-to-face meeting prior to their 1st hospital 
appointment. 
Patients who present with MSDs typically 
receive packages of care from RLHIM. During the 
1st appointment, some patients receive treatment 
immediately, others may receive an initial treatment 
but then have to wait before the beginning of a course 
of treatment. 
OUTCOME MEASURES
A range of outcome measures will be employed 
in order to determine their appropriateness and 
acceptability for accessing integrated packages of 
care for patients with MSDs. 
Sociodemographic Questionnaire
T h e  s o c i o d e m o g r a p h i c  q u e s t i o n n a i r e 
includes: level of education, occupational status, 
first language, religious affiliation and ethnic origin. 
It takes approximately 2 min to complete, and will 
be administered once in the period between the 
1st appointment being booked and attending this 
appointment. 
PEQ
As expectation of benefit has been shown to 
impact on clinical effectiveness,(15) we have developed 
a PEQ to assess patients' expectation of benefit 
from their integrated treatment, and how much faith 
they have in complementary therapies in general, 
both measured on 10-point ordinal scales. The 
PEQ takes approximately 2 min to complete, and 
will be administered once, at the same time as the 
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sociodemographic questionnaire.
Primary Outcome Measures 
The SF-36—Bodily Pain Subscale
The SF-36 is a multi-purpose, short-form health 
survey with 36 questions. It yields an 8-scale profile 
of functional health and well-being scores as well as 
psychometrically-based physical and mental health 
summary measures. It is a generic measure, as 
opposed to one that targets a specific age, disease, 
or treatment group. The internal consistency of the 
SF-36 had been extensively evaluated with most 
studies finding a reliability coefficient (Cronbach's 
alpha) over 0.80.(16)
Bodily pain is one dimension of SF-36 consisting 
of two questions. The bodily pain subscale is an 
accepted, validated and reliable sub-scale, useful for 
making comparisons across populations.(17) 
Secondary Outcome Measures 
The SF-36 —Other Dimensions
In addition to the SF-36 bodily pain dimension, 
there are 34 questions on physical function, physical role, 
general health, and mental health, emotional role, social 
function and vitality. SF-36 has been used and validated 
with numerous studies in a variety of patient populations, 
including patients with MSDs.(18-22) This questionnaire 
has also been suggested for routine use within the 
NHS.(23) The SF-36 (including SF-36 Bodily Pain 
Dimension) takes approximately 10 min to complete. 
BPI-sf
The BPI-sf is a valid and reliable tool for 
evaluating pain status.(24,25) It has been used widely 
for various kind of pain, especially in musculoskeletal 
pain.(26-29) It includes 9 questions and provides 
information on the intensity of pain, along with the 
degree to which the pain interferes with everyday 
Figure 2. Participant Flow
Notes: In routine practice, some patients may have one-off treatment or commence their treatment immediately at T2a, some patients 
may have to wait for their treatment. For those who are put on the waiting list (up to 5 months), an additional evaluation will be administered at 
T2b before their 1st treatment. △Questionnaires include SF-36, BPI-sf, Visual Analogue Scale and modifi ed Client Service Receipt Inventory
Specialist clinician: (1) screen eligibility, (2) put a sticker on eligible patient's referral letter, and (3) 
pass them to Patient Service Department (PSD)
PSD: (1) send informaltion sheet and cover letter with patients' routine appointment letter, (2) call 
and remind all patients about the study and ask perminssion to be contacted
T1–CI and patients get contact. Consent form, sociodemographic questionnaire and PEQ will be 
posted with a reply paid envelope to patients who are interested in taking part
CI follows up non-respondents and invites participants 
for qualitative study
T2a–Baseline Measures (1st assessm):
Participants provide consent and complete △questionnaires on the day of assessment, prior to 
their 1st appointment (face to face) + Qualitative interviews with selected subsample
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functioning. The internal consistency of the BPI-sf 
has been extensively evaluated with studies finding 
a reliability coefficient (Cronbach's alpha) of 0.77 to 
0.91.(30) Numerous studies have used the BPI-sf in a 
variety of patient populations, including patients with 
MSDs.(31) It is routinely used for MSDs at RLHIM. The 
BPI-sf takes approximately 5 min to complete.
Visual Analogue Scale
Visual Analogue Scale (VAS) is a commonly 
used outcome measurement to monitor variations in 
intensity of pain. It will provide additional confi rmation 
together with BPI-sf and SF-36 Bodily Pain subscale 
to validate patients' reports of pain. The VAS takes 
less than 1 min to complete. 
Modifi ed Client Service Receipt Inventory 
Health and social care service utilization will be 
explored by asking participants about quantity/frequency 
of service use. The Client Service Receipt Inventory 
(CSRI) is an internally validated instrument.(32) A modifi ed 
version of the CSRI (mCSRI) has been designed to 
collect retrospective data on the impact of integrated 
medicine approaches on use of our health and social 
care services. The mCSRI takes approximately 10 
min to complete. 
Qualitative Study
In the 1st semi-structured interview, a interview 
schedule with a series of prepared, open-ended 
statements will cover the participants' condition, 
treatments previously used, referral process to RLHIM 
and their expectation of the integrated treatments. The 
2nd semi-structured interview or focus group will cover 
patient's experiences of the integrated treatments 
they received at the RLHIM, their experiences of 
participating in the study, including recruitment, drop-
out and compliance, acceptability of the study design 
and outcome measures. Both interviews and focus 
groups will last 60 min, and will be digitally recorded 
and transcribed verbatim. 
Sample Size
Although a feasibility study does not require 
a sample size calculation, we hope to recruit 150 
patients and anticipate that this will provide a 
suffi ciently large enough sample to capture the range 
of patients and conditions presenting at the RLHIM.
Previously at RLHIM a pragmatic observational 
study was carried out on a group of 152 patients 
(presenting for a variety of conditions) receiving a 
course of autogenic training over 12 months.(33) This 
project demonstrated the feasibility of this approach 
and the ability to recruit and demonstrate change 
after completing the autogenic training programme at 
RLHIM. It is anticipated that there will be more eligible 
patients in the proposed study as MSDs are the group 
of conditions mostly frequently presenting at the 
hospital. 
There were 311 new MSDs referrals in 2010 to 
the RLHIM and estimating that approximately 50% 
would be ineligible or do not consent to take part in 
the study, it is anticipated that there will about 150 
eligible patients. Data on patients who drop out during 
the study will be collected for further comparisons.
For the qualitative study, a limit of 30 patients 
was set for each of the two nested qualitative studies, 
as it is anticipated that this will be a suffi cient sample 
size to ensure theoretical saturation of emergent 
categories and themes.(34)
DATA COLLECTION
Data Collection on Feasibility
During recruitment, data will be recorded on 
number of past/new referrals, eligible patients for the 
study, number of patients consenting/declining to take 
part, and reasons for not participating.
At  the end of  the study,  at tendance for 
appointments, patient follow-up and drop-out/ 
completion rates will be generated from treatment 
logs. Rates of completion of the outcome measures, 
data collection and analysis will be explored by the 
CI. The study timeline as measured by the time 
taken to recruit and complete the study will also be 
evaluated.
Quantitative Data Collection 
Data will be collected at 4 time points (5 if 
patients have delayed treatment, Table 2): T1 (mail) 
after an appointment is arranged but before the 
patient has attended T2a before their 1st treatment; 
T2b (if treatment is delayed, face to face) immediately 
prior to starting their package of treatment; T3, T4, 
(mail) at 4, 8, 12 months respectively after T2a/b; T5 
(mail or interview/focus group for subset) 12 months 
after T2a/b. The CI will post a copy of the SF36, BPI-
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sf, VAS and mCSRI to patients with a reply paid 
envelope. A list of the outcome measures schedule 
is given (Table 2).
Qualitative Data Collection 
Qualitative data will be collected at T2a and T5. 
Interview/focus groups will be conducted at RLHIM, 
patients homes, or other location convenient for 
participating patients. 
DATA ANALYSIS
The analysis of data (both qualitative and 
quantitative) will be undertaken by the CI under the 
supervision of the research team. 
Frequency Data Analysis
Frequency data on the number of past/new 
referrals, eligible patients for the study, number of 
patients consenting to take part and with explanation 
of reasons in detail will be manually entered into 
Microsoft Excel. A record of all patients will be kept 
on: their attendance for treatments, the treatments 
provided, and the completion of questionnaires and 
interview/ focus groups with dates specifi ed. A timeline 
of the whole pilot will inform the future study protocol.
Data Analysis for the Quantitative Pilot Trial
Data from the sociodemographic questionnaire, 
SF36, BPI-sf, VAS and mCSRI will be entered in 
Excel, and analysed using Statistical Packages for 
Social Sciences (SPSS) version 18 using appropriate 
between-group tests. 
The primary time period is the change in scores 
over a 4-month period after starting defi nitive treatment 
and at 12 month follow-up assessment, in order to 
assess the feasibility of measuring the potential long-
term treatment effect. Data on the feasibility of the 
study design including recruitment, compliance, follow-
up, outcome measures, time scale and acceptability 
to patients and clinicians will be used to develop a 
protocol for a full trial. In order to calculate the sample 
size for the full trial, data will be used to calculate the 
effect size. Exploratory data analysis will be conducted 
on all the relevant parameters. If the data is normally 
distributed, an ANOVA will be conducted comparing 
scores in mean of different time points, followed by 
Pearson correlation and regression test for possible 
combinations. If appropriate and if there are suffi cient 
numbers, sub analysis will be conducted to evaluate 
the differences in improvement between different 
categories of patients, for example: patients with 
various MSDs diagnosis; presence of one or multiple 
MSDs; sociodemographic characteristics; package of 
care received, including group treatment or one-to-
one clinics and number of different therapies received. 
Differences between patients who do not complete their 
course of treatment and completers will be evaluated. 
Sensitivity analyses will be performed by varying a wide 
range of parameters in terms of costs.
Patients are routinely discharged from the 
hospital if they fail to attend for an appointment 
on two consecutive occasions. Intention to treat 
analysis using last value carried forward will be 
used, so if patients are discharged before completing 
treatment or are otherwise lost to follow-up, all the 
data collected up to the last point will be used. This 
helps in preventing skewed data and those data will 
be collected for a subgroup analysis, to evaluate the 
differences between those patients and those who 
consistently come to the clinics.
Data Analysis for the Interview/Focus Group
The semi-structured interviews and focus groups 
with patients will be digitally recorded and transcribed 
Table 2. Schedule of Outcome Measures
Measurements
Waiting time between 
referral letter and 
treatment initiation (T1)
Before initiation 
of RLHIM 
treatment (T2a)
Before initiation 
of RLHIM 
treatment (T2b)
4 months after 
T2a/b (T3)
8 months after 
T2a/b (T4)
12 months after 
T2a/b (T5)
Sociodemographics X
PEQ X
SF-36 X X X X X
BPI-sf X X X X X
VAS X X X X X
mCSRI X X X X X
Note: X rpresents the time point at which this questionnaire data will be collected
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verbatim. Qualitative data will be analysed thematically 
and major categories and themes identified using 
NVivo10. 
DISCUSSION
This study is developed based on data from 
everyday practice at the RLHIM. Based on this we plan 
a feasibility study to evaluate the effectiveness and cost 
effectiveness of the integrated package of treatment for 
MSDs provided at the RLHIM. We plan to recruit 150 
patients by January 2014.
There is a dearth of publ ished research 
evaluating the impact of integrated treatments for 
MSDs in a NHS setting. This research will inform 
all aspects of the design of a future trial including 
recruitment, retention, suitability of the outcome 
measures, patients views and experience. A defi nitive 
trial is important because these conditions are highly 
prevalent and complementary therapies often used 
by patients, although usually outside NHS settings. 
Such a trial would improve policy, inform guidelines 
and decision-making for MSDs practitioners and 
MSDs patients; provide policymakers/commissioners 
with economic evidence, which may faci l i tate 
optimal resource allocation decisions; and to inform 
clinical practice for future patient care at the RLHIM 
and elsewhere by suggesting which treatment 
combinations are associated with the best outcomes 
for MSDs patients.
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